Stay updated on INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Sign up to get notified when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.

Latest updates to the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check20 days agoChange Detected- Updated version to v3.2.0 and removed the Gastrointestinal stromal tumor resource from Genetic and Rare Diseases Information Center. - Added a government funding lapse notice with operating-status guidance for users.SummaryDifference2%

- Check27 days agoChange DetectedUpdated the page version from v3.0.2 to v3.1.0 to reflect a newer release.SummaryDifference0.1%

- Check41 days agoChange DetectedUpdate to Revision: v3.0.2 from v3.0.1; removal of 'Back to Top' is a minor UI change and does not affect core content.SummaryDifference0.1%

- Check48 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.1%

- Check56 days agoChange DetectedThe web page has been updated to include new facility names and locations, as well as detailed references to recent studies on gastrointestinal stromal tumors and the drug ripretinib, while removing some previous location terms and outdated references.SummaryDifference15%

- Check70 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INTRIGUE: Ripretinib vs Sunitinib in GIST Clinical Trial page.